Innocoll : Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers

April 17, 2008 –Innocoll, Inc., a privately-held biopharmaceutical company, announced that the second of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing. CollaRx GENTAMICIN TOPICAL is a biodegradable and fully resorbable Gentamicin-Collagen Sponge formulated and manufactured using Innocoll’s proprietary collagen-based drug delivery technology, CollaRx. Upon application to a wound, the product releases gentamicin, a broad-spectrum, aminoglycoside antibiotic (having a concentration-dependent mechanism of action), for local action. This achieves a high concentration of drug at the target tissue, while maintaining low systemic levels well below the toxicity threshold... Innocoll 's Press release -

Innocoll , phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers

September 26, 2007 – Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:
.....CollaRx® GENTAMICIN TOPICAL to commence a series of phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers... Innocoll 's Press Release -